Progyny, Inc. (PGNY)
NASDAQ: PGNY · Real-Time Price · USD
23.63
+0.13 (0.55%)
Jul 31, 2025, 1:00 PM - Market open
CTI BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $24, which forecasts a 1.57% increase in the stock price over the next year. The lowest target is $17 and the highest is $28.
Price Target: $24.00 (+1.57%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 6 | 5 | 5 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $24 → $27 | Hold | Maintains | $24 → $27 | +14.26% | Jul 17, 2025 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $28 | Hold → Buy | Upgrades | $28 | +18.49% | Jul 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $23 → $21 | Hold | Maintains | $23 → $21 | -11.13% | May 12, 2025 |
| BTIG | BTIG | Hold → Strong Buy Upgrades $28 | Hold → Strong Buy | Upgrades | $28 | +18.49% | Mar 31, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $17 → $23 | Hold | Maintains | $17 → $23 | -2.67% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
1.26B
from 1.17B
Increased by 7.61%
Revenue Next Year
1.40B
from 1.26B
Increased by 11.39%
EPS This Year
0.56
from 0.57
Decreased by -2.07%
EPS Next Year
0.95
from 0.56
Increased by 69.94%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.3B | 1.5B | 1.7B | ||
| Avg | 1.3B | 1.4B | 1.6B | ||
| Low | 1.2B | 1.3B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.2% | 20.7% | 20.2% | ||
| Avg | 7.6% | 11.4% | 13.0% | ||
| Low | 1.6% | 2.3% | 4.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.65 | 1.97 | 1.60 | ||
| Avg | 0.56 | 0.95 | 1.11 | ||
| Low | 0.50 | 0.60 | 0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.2% | 253.6% | 68.2% | ||
| Avg | -2.1% | 69.9% | 17.4% | ||
| Low | -12.3% | 7.1% | -21.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.